APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Neutropenia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chemotherapy Induced Neutropenia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Neutropenia Drug Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Neutropenia Drug Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Neutropenia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Neutropenia Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Neutropenia Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Chemotherapy Induced Neutropenia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chemotherapy Induced Neutropenia Drug include Sandoz International GmbH, Pfizer Inc, USV Pvt Ltd, Richter Gedeon Nyrt, Reliance Life Sciences Pvt Ltd, Pfenex Inc, Pangen Biotech Inc., Octapharma AG and Nohla Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chemotherapy Induced Neutropenia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy Induced Neutropenia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy Induced Neutropenia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy Induced Neutropenia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy Induced Neutropenia Drug Segment by Company

Sandoz International GmbH

Pfizer Inc

USV Pvt Ltd

Richter Gedeon Nyrt

Reliance Life Sciences Pvt Ltd

Pfenex Inc

Pangen Biotech Inc.

Octapharma AG

Nohla Therapeutics Inc

Myelo Therapeutics GmbH

Mycenax Biotech Inc

Lupin Ltd

Intas Pharmaceuticals Ltd

Hanmi Pharmaceuticals Co Ltd

GlycoMimetics Inc

Genexine Inc

Generon (Shanghai) Corp Ltd

Gene Techno Science Co Ltd

Dr. Reddy's Laboratories Ltd

Cinfa Biotech SL

Chong Kun Dang Pharmaceutical Corp

Cellerant Therapeutics Inc

Bolder Biotechnology Inc

Biocon Ltd

BeyondSpring Pharmaceuticals Inc

Chemotherapy Induced Neutropenia Drug Segment by Type

Filgrastim

NLA-101

GW-003

F-627

BBT-018

Others

Chemotherapy Induced Neutropenia Drug Segment by Application

Hospital

Clinic

Others

Chemotherapy Induced Neutropenia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Neutropenia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Neutropenia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Neutropenia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy Induced Neutropenia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy Induced Neutropenia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chemotherapy Induced Neutropenia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chemotherapy Induced Neutropenia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy Induced Neutropenia Drug Industry Trends Table 2. Chemotherapy Induced Neutropenia Drug Industry Drivers Table 3. Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges Table 4. Chemotherapy Induced Neutropenia Drug Industry Restraints Table 5. Global Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chemotherapy Induced Neutropenia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers Table 9. Global Chemotherapy Induced Neutropenia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Chemotherapy Induced Neutropenia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chemotherapy Induced Neutropenia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chemotherapy Induced Neutropenia Drug Manufacturers, Product Type & Application Table 13. Global Chemotherapy Induced Neutropenia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy Induced Neutropenia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Filgrastim Table 17. Major Manufacturers of NLA-101 Table 18. Major Manufacturers of GW-003 Table 19. Major Manufacturers of F-627 Table 20. Major Manufacturers of BBT-018 Table 21. Major Manufacturers of Others Table 22. Global Chemotherapy Induced Neutropenia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2026) Table 26. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2027-2032) Table 27. Global Chemotherapy Induced Neutropenia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2026) Table 31. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Chemotherapy Induced Neutropenia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2026) Table 39. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2027-2032) Table 40. Global Chemotherapy Induced Neutropenia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2026) Table 44. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2027-2032) Table 45. Global Chemotherapy Induced Neutropenia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Region (2021-2026) Table 48. Global Chemotherapy Induced Neutropenia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Chemotherapy Induced Neutropenia Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Chemotherapy Induced Neutropenia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2021-2026) Table 66. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2027-2032) Table 67. Sandoz International GmbH Company Information Table 68. Sandoz International GmbH Business Overview Table 69. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 71. Sandoz International GmbH Recent Development Table 72. Pfizer Inc Company Information Table 73. Pfizer Inc Business Overview Table 74. Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 76. Pfizer Inc Recent Development Table 77. USV Pvt Ltd Company Information Table 78. USV Pvt Ltd Business Overview Table 79. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 81. USV Pvt Ltd Recent Development Table 82. Richter Gedeon Nyrt Company Information Table 83. Richter Gedeon Nyrt Business Overview Table 84. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio Table 86. Richter Gedeon Nyrt Recent Development Table 87. Reliance Life Sciences Pvt Ltd Company Information Table 88. Reliance Life Sciences Pvt Ltd Business Overview Table 89. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 91. Reliance Life Sciences Pvt Ltd Recent Development Table 92. Pfenex Inc Company Information Table 93. Pfenex Inc Business Overview Table 94. Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 96. Pfenex Inc Recent Development Table 97. Pangen Biotech Inc. Company Information Table 98. Pangen Biotech Inc. Business Overview Table 99. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio Table 101. Pangen Biotech Inc. Recent Development Table 102. Octapharma AG Company Information Table 103. Octapharma AG Business Overview Table 104. Octapharma AG Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio Table 106. Octapharma AG Recent Development Table 107. Nohla Therapeutics Inc Company Information Table 108. Nohla Therapeutics Inc Business Overview Table 109. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 111. Nohla Therapeutics Inc Recent Development Table 112. Myelo Therapeutics GmbH Company Information Table 113. Myelo Therapeutics GmbH Business Overview Table 114. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 116. Myelo Therapeutics GmbH Recent Development Table 117. Mycenax Biotech Inc Company Information Table 118. Mycenax Biotech Inc Business Overview Table 119. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 121. Mycenax Biotech Inc Recent Development Table 122. Lupin Ltd Company Information Table 123. Lupin Ltd Business Overview Table 124. Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 126. Lupin Ltd Recent Development Table 127. Intas Pharmaceuticals Ltd Company Information Table 128. Intas Pharmaceuticals Ltd Business Overview Table 129. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 131. Intas Pharmaceuticals Ltd Recent Development Table 132. Hanmi Pharmaceuticals Co Ltd Company Information Table 133. Hanmi Pharmaceuticals Co Ltd Business Overview Table 134. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 136. Hanmi Pharmaceuticals Co Ltd Recent Development Table 137. GlycoMimetics Inc Company Information Table 138. GlycoMimetics Inc Business Overview Table 139. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 141. GlycoMimetics Inc Recent Development Table 142. Genexine Inc Company Information Table 143. Genexine Inc Business Overview Table 144. Genexine Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 146. Genexine Inc Recent Development Table 147. Generon (Shanghai) Corp Ltd Company Information Table 148. Generon (Shanghai) Corp Ltd Business Overview Table 149. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 151. Generon (Shanghai) Corp Ltd Recent Development Table 152. Gene Techno Science Co Ltd Company Information Table 153. Gene Techno Science Co Ltd Business Overview Table 154. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 156. Gene Techno Science Co Ltd Recent Development Table 157. Dr. Reddy's Laboratories Ltd Company Information Table 158. Dr. Reddy's Laboratories Ltd Business Overview Table 159. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 161. Dr. Reddy's Laboratories Ltd Recent Development Table 162. Cinfa Biotech SL Company Information Table 163. Cinfa Biotech SL Business Overview Table 164. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio Table 166. Cinfa Biotech SL Recent Development Table 167. Chong Kun Dang Pharmaceutical Corp Company Information Table 168. Chong Kun Dang Pharmaceutical Corp Business Overview Table 169. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio Table 171. Chong Kun Dang Pharmaceutical Corp Recent Development Table 172. Cellerant Therapeutics Inc Company Information Table 173. Cellerant Therapeutics Inc Business Overview Table 174. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 175. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 176. Cellerant Therapeutics Inc Recent Development Table 177. Bolder Biotechnology Inc Company Information Table 178. Bolder Biotechnology Inc Business Overview Table 179. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 180. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 181. Bolder Biotechnology Inc Recent Development Table 182. Biocon Ltd Company Information Table 183. Biocon Ltd Business Overview Table 184. Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 185. Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 186. Biocon Ltd Recent Development Table 187. BeyondSpring Pharmaceuticals Inc Company Information Table 188. BeyondSpring Pharmaceuticals Inc Business Overview Table 189. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 190. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 191. BeyondSpring Pharmaceuticals Inc Recent Development Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Chemotherapy Induced Neutropenia Drug Distributors List Table 195. Chemotherapy Induced Neutropenia Drug Customers List Table 196. Research Programs/Design for This Report Table 197. Authors List of This Report Table 198. Secondary Sources Table 199. Primary Sources List of Figures Figure 1. Chemotherapy Induced Neutropenia Drug Product Image Figure 2. Global Chemotherapy Induced Neutropenia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Neutropenia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy Induced Neutropenia Drug Sales (2021-2032) & (K Units) Figure 5. Global Chemotherapy Induced Neutropenia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Filgrastim Image Figure 9. NLA-101 Image Figure 10. GW-003 Image Figure 11. F-627 Image Figure 12. BBT-018 Image Figure 13. Others Image Figure 14. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Chemotherapy Induced Neutropenia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2032) Figure 17. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Chemotherapy Induced Neutropenia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2032) Figure 26. Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 43. China Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Chemotherapy Induced Neutropenia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Chemotherapy Induced Neutropenia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Chemotherapy Induced Neutropenia Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Chemotherapy Induced Neutropenia Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Chemotherapy Induced Neutropenia Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Chemotherapy Induced Neutropenia Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Chemotherapy Induced Neutropenia Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • NLA-101
  • GW-003
  • F-627
  • BBT-018
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • Pfizer Inc
  • USV Pvt Ltd
  • Richter Gedeon Nyrt
  • Reliance Life Sciences Pvt Ltd
  • Pfenex Inc
  • Pangen Biotech Inc.
  • Octapharma AG
  • Nohla Therapeutics Inc
  • Myelo Therapeutics GmbH
  • Mycenax Biotech Inc
  • Lupin Ltd
  • Intas Pharmaceuticals Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • GlycoMimetics Inc
  • Genexine Inc
  • Generon (Shanghai) Corp Ltd
  • Gene Techno Science Co Ltd
  • Dr. Reddy's Laboratories Ltd
  • Cinfa Biotech SL
  • Chong Kun Dang Pharmaceutical Corp
  • Cellerant Therapeutics Inc
  • Bolder Biotechnology Inc
  • Biocon Ltd
  • BeyondSpring Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chemotherapy Induced Neutropenia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chemotherapy Induced Neutropenia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chemotherapy Induced Neutropenia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chemotherapy Induced Neutropenia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chemotherapy Induced Neutropenia Drug Market Dynamics
  1. 2.1 Chemotherapy Induced Neutropenia Drug Industry Trends
  2. 2.2 Chemotherapy Induced Neutropenia Drug Industry Drivers
  3. 2.3 Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Neutropenia Drug Industry Restraints
3 Chemotherapy Induced Neutropenia Drug Market by Manufacturers
  1. 3.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chemotherapy Induced Neutropenia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chemotherapy Induced Neutropenia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chemotherapy Induced Neutropenia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy Induced Neutropenia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chemotherapy Induced Neutropenia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Chemotherapy Induced Neutropenia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy Induced Neutropenia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy Induced Neutropenia Drug Tier 1, Tier 2, and Tier 3
4 Chemotherapy Induced Neutropenia Drug Market by Type
  1. 4.1 Chemotherapy Induced Neutropenia Drug Type Introduction
  2. 4.1.1 Filgrastim
  3. 4.1.2 NLA-101
  4. 4.1.3 GW-003
  5. 4.1.4 F-627
  6. 4.1.5 BBT-018
  7. 4.1.6 Others
  8. 4.2 Global Chemotherapy Induced Neutropenia Drug Sales by Type
  9. 4.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Chemotherapy Induced Neutropenia Drug Revenue by Type
  13. 4.3.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2032)
5 Chemotherapy Induced Neutropenia Drug Market by Application
  1. 5.1 Chemotherapy Induced Neutropenia Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chemotherapy Induced Neutropenia Drug Sales by Application
  6. 5.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chemotherapy Induced Neutropenia Drug Revenue by Application
  10. 5.3.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2032)
6 Global Chemotherapy Induced Neutropenia Drug Sales by Region
  1. 6.1 Global Chemotherapy Induced Neutropenia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Chemotherapy Induced Neutropenia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chemotherapy Induced Neutropenia Drug Revenue by Region
  1. 7.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Region
  2. 7.1.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chemotherapy Induced Neutropenia Drug Revenue (2021-2032)
  8. 7.2.2 North America Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chemotherapy Induced Neutropenia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chemotherapy Induced Neutropenia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sandoz International GmbH
  2. 8.1.1 Sandoz International GmbH Company Information
  3. 8.1.2 Sandoz International GmbH Business Overview
  4. 8.1.3 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  6. 8.1.5 Sandoz International GmbH Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 USV Pvt Ltd
  14. 8.3.1 USV Pvt Ltd Company Information
  15. 8.3.2 USV Pvt Ltd Business Overview
  16. 8.3.3 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  18. 8.3.5 USV Pvt Ltd Recent Developments
  19. 8.4 Richter Gedeon Nyrt
  20. 8.4.1 Richter Gedeon Nyrt Company Information
  21. 8.4.2 Richter Gedeon Nyrt Business Overview
  22. 8.4.3 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio
  24. 8.4.5 Richter Gedeon Nyrt Recent Developments
  25. 8.5 Reliance Life Sciences Pvt Ltd
  26. 8.5.1 Reliance Life Sciences Pvt Ltd Company Information
  27. 8.5.2 Reliance Life Sciences Pvt Ltd Business Overview
  28. 8.5.3 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  30. 8.5.5 Reliance Life Sciences Pvt Ltd Recent Developments
  31. 8.6 Pfenex Inc
  32. 8.6.1 Pfenex Inc Company Information
  33. 8.6.2 Pfenex Inc Business Overview
  34. 8.6.3 Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  36. 8.6.5 Pfenex Inc Recent Developments
  37. 8.7 Pangen Biotech Inc.
  38. 8.7.1 Pangen Biotech Inc. Company Information
  39. 8.7.2 Pangen Biotech Inc. Business Overview
  40. 8.7.3 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio
  42. 8.7.5 Pangen Biotech Inc. Recent Developments
  43. 8.8 Octapharma AG
  44. 8.8.1 Octapharma AG Company Information
  45. 8.8.2 Octapharma AG Business Overview
  46. 8.8.3 Octapharma AG Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio
  48. 8.8.5 Octapharma AG Recent Developments
  49. 8.9 Nohla Therapeutics Inc
  50. 8.9.1 Nohla Therapeutics Inc Company Information
  51. 8.9.2 Nohla Therapeutics Inc Business Overview
  52. 8.9.3 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  54. 8.9.5 Nohla Therapeutics Inc Recent Developments
  55. 8.10 Myelo Therapeutics GmbH
  56. 8.10.1 Myelo Therapeutics GmbH Company Information
  57. 8.10.2 Myelo Therapeutics GmbH Business Overview
  58. 8.10.3 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  60. 8.10.5 Myelo Therapeutics GmbH Recent Developments
  61. 8.11 Mycenax Biotech Inc
  62. 8.11.1 Mycenax Biotech Inc Company Information
  63. 8.11.2 Mycenax Biotech Inc Business Overview
  64. 8.11.3 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  66. 8.11.5 Mycenax Biotech Inc Recent Developments
  67. 8.12 Lupin Ltd
  68. 8.12.1 Lupin Ltd Company Information
  69. 8.12.2 Lupin Ltd Business Overview
  70. 8.12.3 Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  72. 8.12.5 Lupin Ltd Recent Developments
  73. 8.13 Intas Pharmaceuticals Ltd
  74. 8.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 8.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 8.13.3 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  78. 8.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 8.14 Hanmi Pharmaceuticals Co Ltd
  80. 8.14.1 Hanmi Pharmaceuticals Co Ltd Company Information
  81. 8.14.2 Hanmi Pharmaceuticals Co Ltd Business Overview
  82. 8.14.3 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  84. 8.14.5 Hanmi Pharmaceuticals Co Ltd Recent Developments
  85. 8.15 GlycoMimetics Inc
  86. 8.15.1 GlycoMimetics Inc Company Information
  87. 8.15.2 GlycoMimetics Inc Business Overview
  88. 8.15.3 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  90. 8.15.5 GlycoMimetics Inc Recent Developments
  91. 8.16 Genexine Inc
  92. 8.16.1 Genexine Inc Company Information
  93. 8.16.2 Genexine Inc Business Overview
  94. 8.16.3 Genexine Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  96. 8.16.5 Genexine Inc Recent Developments
  97. 8.17 Generon (Shanghai) Corp Ltd
  98. 8.17.1 Generon (Shanghai) Corp Ltd Company Information
  99. 8.17.2 Generon (Shanghai) Corp Ltd Business Overview
  100. 8.17.3 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  102. 8.17.5 Generon (Shanghai) Corp Ltd Recent Developments
  103. 8.18 Gene Techno Science Co Ltd
  104. 8.18.1 Gene Techno Science Co Ltd Company Information
  105. 8.18.2 Gene Techno Science Co Ltd Business Overview
  106. 8.18.3 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  108. 8.18.5 Gene Techno Science Co Ltd Recent Developments
  109. 8.19 Dr. Reddy's Laboratories Ltd
  110. 8.19.1 Dr. Reddy's Laboratories Ltd Company Information
  111. 8.19.2 Dr. Reddy's Laboratories Ltd Business Overview
  112. 8.19.3 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  114. 8.19.5 Dr. Reddy's Laboratories Ltd Recent Developments
  115. 8.20 Cinfa Biotech SL
  116. 8.20.1 Cinfa Biotech SL Company Information
  117. 8.20.2 Cinfa Biotech SL Business Overview
  118. 8.20.3 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio
  120. 8.20.5 Cinfa Biotech SL Recent Developments
  121. 8.21 Chong Kun Dang Pharmaceutical Corp
  122. 8.21.1 Chong Kun Dang Pharmaceutical Corp Company Information
  123. 8.21.2 Chong Kun Dang Pharmaceutical Corp Business Overview
  124. 8.21.3 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio
  126. 8.21.5 Chong Kun Dang Pharmaceutical Corp Recent Developments
  127. 8.22 Cellerant Therapeutics Inc
  128. 8.22.1 Cellerant Therapeutics Inc Company Information
  129. 8.22.2 Cellerant Therapeutics Inc Business Overview
  130. 8.22.3 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  132. 8.22.5 Cellerant Therapeutics Inc Recent Developments
  133. 8.23 Bolder Biotechnology Inc
  134. 8.23.1 Bolder Biotechnology Inc Company Information
  135. 8.23.2 Bolder Biotechnology Inc Business Overview
  136. 8.23.3 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  138. 8.23.5 Bolder Biotechnology Inc Recent Developments
  139. 8.24 Biocon Ltd
  140. 8.24.1 Biocon Ltd Company Information
  141. 8.24.2 Biocon Ltd Business Overview
  142. 8.24.3 Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  144. 8.24.5 Biocon Ltd Recent Developments
  145. 8.25 BeyondSpring Pharmaceuticals Inc
  146. 8.25.1 BeyondSpring Pharmaceuticals Inc Company Information
  147. 8.25.2 BeyondSpring Pharmaceuticals Inc Business Overview
  148. 8.25.3 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  150. 8.25.5 BeyondSpring Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy Induced Neutropenia Drug Value Chain Analysis
  2. 9.1.1 Chemotherapy Induced Neutropenia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy Induced Neutropenia Drug Production Mode & Process
  6. 9.2 Chemotherapy Induced Neutropenia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy Induced Neutropenia Drug Distributors
  9. 9.2.3 Chemotherapy Induced Neutropenia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst